C.‐M. Wendtner

1.0k total citations
30 papers, 662 citations indexed

About

C.‐M. Wendtner is a scholar working on Genetics, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, C.‐M. Wendtner has authored 30 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 10 papers in Pathology and Forensic Medicine and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in C.‐M. Wendtner's work include Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (9 papers) and Virus-based gene therapy research (5 papers). C.‐M. Wendtner is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (9 papers) and Virus-based gene therapy research (5 papers). C.‐M. Wendtner collaborates with scholars based in Germany, United States and United Kingdom. C.‐M. Wendtner's co-authors include Michael Hallek, Stephan Stilgenbauer, Matthias Ritgen, Barbara Eichhorst, Bertold Emmerich, Hartmut Döhner, Michael Kneba, Robert Busch, Hartmut Campe and Guenter Fingerle-Rowson and has published in prestigious journals such as Journal of Clinical Oncology, Oncogene and Annals of Oncology.

In The Last Decade

C.‐M. Wendtner

28 papers receiving 636 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
C.‐M. Wendtner Germany 11 336 317 202 182 128 30 662
Talha Munir United Kingdom 17 524 1.6× 356 1.1× 316 1.6× 86 0.5× 77 0.6× 81 754
J. Jackson Ireland 14 258 0.8× 132 0.4× 133 0.7× 37 0.2× 77 0.6× 28 930
J. M. Castrillo Spain 11 78 0.2× 487 1.5× 414 2.0× 87 0.5× 238 1.9× 37 912
Deepa Jagadeesh United States 17 273 0.8× 660 2.1× 170 0.8× 65 0.4× 652 5.1× 123 1.1k
Jieun Uhm Canada 16 182 0.5× 63 0.2× 112 0.6× 275 1.5× 360 2.8× 57 876
Neelam Siddiqui Pakistan 15 53 0.2× 265 0.8× 42 0.2× 174 1.0× 255 2.0× 67 724
G. De Marchi Italy 12 204 0.6× 143 0.5× 135 0.7× 79 0.4× 56 0.4× 28 906
Elizabeth Margolskee United States 13 128 0.4× 174 0.5× 73 0.4× 64 0.4× 166 1.3× 35 494
Claudia Alpini Italy 16 44 0.1× 152 0.5× 197 1.0× 68 0.4× 44 0.3× 32 835
Masanao Teramura Japan 16 184 0.5× 121 0.4× 333 1.6× 53 0.3× 143 1.1× 43 872

Countries citing papers authored by C.‐M. Wendtner

Since Specialization
Citations

This map shows the geographic impact of C.‐M. Wendtner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C.‐M. Wendtner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C.‐M. Wendtner more than expected).

Fields of papers citing papers by C.‐M. Wendtner

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C.‐M. Wendtner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C.‐M. Wendtner. The network helps show where C.‐M. Wendtner may publish in the future.

Co-authorship network of co-authors of C.‐M. Wendtner

This figure shows the co-authorship network connecting the top 25 collaborators of C.‐M. Wendtner. A scholar is included among the top collaborators of C.‐M. Wendtner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C.‐M. Wendtner. C.‐M. Wendtner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Al‐Sawaf, Othman, Sandra Robrecht, Anna‐Maria Fink, et al.. (2021). THE CLL‐RT1 TRIAL: A MULTICENTER PHASE‐2 TRIAL OF ZANUBRUTINIB, A BTK INHIBITOR, PLUS TISLELIZUMAB, A PD‐1 INHIBITOR, FOR PATIENTS WITH RICHTER TRANSFORMATION. Hematological Oncology. 39(S2). 3 indexed citations
3.
Al‐Sawaf, Othman, Sandra Robrecht, Jasmin Bahlo, et al.. (2020). Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 35(1). 169–176. 62 indexed citations
4.
Biehl, Lena M., Jens Panse, Marcus Hentrich, et al.. (2016). A randomized trial on chlorhexidine dressings for the prevention of catheter-related bloodstream infections in neutropenic patients. Annals of Oncology. 27(10). 1916–1922. 24 indexed citations
5.
Schmid-Wendtner, M.-H., et al.. (2015). Hautveränderungen bei malignen hämatologischen Erkrankungen. Der Hautarzt. 66(8). 625–635. 3 indexed citations
6.
7.
Seilmaier, Michael, et al.. (2013). Schwere orale Mukositis bei einem Patienten mit HIV-Infektion. DMW - Deutsche Medizinische Wochenschrift. 138(31/32). 1601–1605. 5 indexed citations
8.
Leskov, Ilya, Christian P. Pallasch, Adam Drake, et al.. (2012). Rapid generation of human B-cell lymphomas via combined expression of Myc and Bcl2 and their use as a preclinical model for biological therapies. Oncogene. 32(8). 1066–1072. 35 indexed citations
9.
Issels, Rolf D., Rüdiger P. Laubender, Ulrich Mansmann, et al.. (2011). Effect of FNCLCC grade 2 versus grade 3 on survival after neoadjuvant chemotherapy (NAC) plus or minus regional hyperthermia (RHT) in soft tissue sarcomas (STS): An analysis of the EORTC-ESHO Intergroup phase III study.. Journal of Clinical Oncology. 29(15_suppl). 10021–10021. 1 indexed citations
10.
Voth, Harald, Jennifer Landsberg, Torsten Hinz, et al.. (2011). Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence‐based review of the literature. Journal of the European Academy of Dermatology and Venereology. 25(12). 1385–1391. 38 indexed citations
11.
Wendtner, C.‐M., et al.. (2010). Multimodale Therapiekonzepte bei Weichteilsarkomen. Der Internist. 51(11). 1388–1396. 4 indexed citations
12.
Österborg, Anders, R. Foà, R. F. Bezares, et al.. (2009). Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia. Leukemia. 23(11). 1980–1988. 60 indexed citations
13.
Montemurro, Michael, Patrick Schöffski, Peter Reichardt, et al.. (2009). Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib. European Journal of Cancer. 45(13). 2293–2297. 109 indexed citations
14.
15.
Kofler, David M., Hildegard Büning, Christine Mayr, et al.. (2004). Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors. Gene Therapy. 11(18). 1416–1424. 9 indexed citations
16.
Hallek, Michael, et al.. (2001). Grundlagen der GentherapiePrinzipien und Stand der Entwicklung. Der Internist. 42(10). 1306–1313. 2 indexed citations
17.
Wendtner, C.‐M., Barbara Schmitt, Mathias Wilhelm, et al.. (1999). Redefining the therapeutic goals in chronic lymphocytic leukemia: Towards an evidence-based, risk-adapted therapy. Annals of Oncology. 10(5). 505–510. 11 indexed citations
18.
Schmid, M.-H., et al.. (1999). Pyoderma gangrenosum associated with the secondary antiphospholipid syndrome.. PubMed. 8(1). 45–7. 27 indexed citations
19.
Wendtner, C.‐M., Raymund Buhmann, H. Kolb, Bertold Emmerich, & Michael Hallek. (1999). Rezidivierender Schwindel und Synkopen bei einer Patientin mit Eosinophilie. Der Internist. 40(3). 305–310. 1 indexed citations
20.
Rădulescu, Radu & C.‐M. Wendtner. (1993). Hormone and growth factor subunits: a novel perception of cell growth regulation. Journal of Endocrinology. 139(1). 1–7. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Talha Munir Breakdown of academic impact, for papers by J. Jackson Breakdown of academic impact, for papers by J. M. Castrillo Breakdown of academic impact, for papers by Deepa Jagadeesh Breakdown of academic impact, for papers by Jieun Uhm Breakdown of academic impact, for papers by Neelam Siddiqui Breakdown of academic impact, for papers by G. De Marchi Breakdown of academic impact, for papers by Elizabeth Margolskee Breakdown of academic impact, for papers by Claudia Alpini Breakdown of academic impact, for papers by Masanao Teramura
Rankless by CCL
2026